Enzalutamide + Abiraterone acetate
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostatic Neoplasms, Castration-Resistant
Conditions
Prostatic Neoplasms, Castration-Resistant
Trial Timeline
Jul 24, 2023 โ Feb 14, 2025
NCT ID
NCT05968599About Enzalutamide + Abiraterone acetate
Enzalutamide + Abiraterone acetate is a pre-clinical stage product being developed by Astellas Pharma for Prostatic Neoplasms, Castration-Resistant. The current trial status is completed. This product is registered under clinical trial identifier NCT05968599. Target conditions include Prostatic Neoplasms, Castration-Resistant.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05968599 | Pre-clinical | Completed |
Competing Products
20 competing products in Prostatic Neoplasms, Castration-Resistant